During the past decade, Kaluga Regional Hospital conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 3 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kaluga Regional Hospital" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Kaluga Regional Hospital" are "Crohn Disease" (3 trials), "Cardiovascular Disease" (2 trials), "Chronic Lymphocytic Leukemia" (1 trials), "Multiple Sclerosis" (1 trials) and "Myelodysplastic Syndromes" (1 trials). Many other conditions were trialed in "Kaluga Regional Hospital" in a lesser frequency.

Most popular intervention types in "Kaluga Regional Hospital" are "Drug" (8 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Ozanimod" (3 trials), "bococizumab (PF-04950615)" (2 trials), "Avonex" (1 trials) and "BIIB033" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kaluga Regional Hospital" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Kaluga Regional Hospital". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Kaluga Regional Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Kaluga Regional Hospital, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".